Quantcast
Last updated on April 18, 2014 at 11:01 EDT

Latest Stem cell treatments Stories

2014-01-13 12:27:02

ROCKVILLE, Md., Jan. 13, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in the Phase I/II NSI-566 stem cell trial to treat motor deficits from ischemic stroke at BaYi Brain Hospital in Beijing, China. The patient received treatment on December 27, 2013 and has now returned home. The trial is sponsored by Neuralstem's wholly-owned subsidiary, Neuralstem China (Suzhou Sun-Now Biopharmaceutical Co. Ltd.), which was formed to develop...

2014-01-10 23:03:41

The global nerve repair and regeneration market is segmented into peripheral nerve repair and neuromodulation segments. http://www.marketsandmarkets.com/Market-Reports/nerve-repair-regeneration-market-883.html (PRWEB) January 10, 2014 The “Nerve Repair & Regeneration Market by Xenografts (Conduits, Protectors), Neuromodulation [Internal (Spinal Cord, Deep Brain)], External (Transcranial Magnetic)], Surgery [Direct Nerve Repair, Grafting, Stem Cell] - Global Trend & Forecast to...

2014-01-09 08:29:26

MONT-SAINT-GUIBERT, Belgium, January 9, 2014 /PRNewswire/ -- Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, announces today that the U.S. Food and Drug Administration (FDA) has authorized the Company's Investigational New Drug (IND) application for clinical testing of the Company's proprietary regenerative medicine...

2014-01-09 08:29:14

ROCKVILLE, Md., Jan. 9, 2014 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that on January 8, 2014, it closed on a $20 million investment from leading institutional and accredited investors in a registered direct placement (the "Offering") of 6,872,859 shares of common stock at a price of $2.91 per share. In addition, the Company issued to the investors in the Offering warrants to purchase common stock equal to one-half of the number of shares purchased by the...

2014-01-09 08:28:41

BEIJING, Jan. 9, 2014 /PRNewswire/ -- Premature ovarian failure (POF) is an illness seen in women under 40 years old who suffer from amenorrhea. Their blood level FSH stays over 40IU/L, with E2 under the level of 100pmol/L and P under the level of 2nmol/L. Symptoms may appear to be similar to the emergence of menopause, such as anxiety, depression, irritability, varying degrees of hot flashes and sweat, vaginal dryness, decreased libido, infertility and so on. POF is a complex...

2014-01-08 17:39:58

UCSF-led study sheds light on muscle-to-bone transformation Researchers have developed a new way to study bone disorders and bone growth, using stem cells from patients afflicted with a rare, genetic bone disease. The approach, based on Nobel-Prize winning techniques, could illuminate the illness, in which muscles and tendons progressively turn into bone, and addresses the similar destructive process that afflicts a growing number of veterans who have suffered blast injuries — including...

2014-01-08 12:29:43

LONDON, Jan. 8, 2014 /PRNewswire/ -- Edison's comprehensive report on Cardio3 BioSciences, Healing failing hearts, analyses its C-Cure heart regenerative product, which uses a mix of powerful cell-signalling molecules to programme autologous stem cells to develop into heart muscle. This makes C-Cure a potentially powerful novel treatment for patients with weakened, scarred hearts, usually due to previous heart attacks. C-Cure showed positive efficacy endpoints in Phase II and median...

2014-01-07 08:30:21

StemGenex is now providing access to the latest stem cell treatment options for patients diagnosed with Diabetes. These treatments are being studied with expertise by board certified MD's in the United States. LA JOLLA, Calif., Jan. 7, 2014 /PRNewswire/ -- According to The American Diabetes Association there are over 25 million people in the US living with diabetes. These patients are suffering from complications such as heart disease, stroke, high blood pressure, blindness, kidney...

2014-01-06 08:25:38

LAS VEGAS, Jan. 6, 2014 /PRNewswire/ -- Cord Blood America, Inc. (www.cordblood-america.com) (OTC Bulletin Board: CBAI) ("CBAI" or the "Company") today announced it has achieved AABB accreditation for cell therapy activity associated with cord blood processing, storage and distribution. "As we embark on the new year of 2014, I cannot think of a better way to validate our operations and jump start our efforts this year than to state publicly that we have earned our AABB...

2013-12-27 10:29:35

Stem cell-based gene therapy holds promise for the treatment of devastating genetic skin diseases, but the long-term clinical outcomes of this approach have been unclear. In a study online December 26th in the ISSCR's journal Stem Cell Reports, published by Cell Press, researchers evaluated a patient with a genetic skin disorder known as epidermolysis bullosa (EB) nearly seven years after he had undergone a gene therapy procedure as part of a clinical trial. The study revealed that a small...